Molecular Diagnostics: A Rapidly Shifting Commercial and Technology Landscape

By Lucy Sannes, PhD, MBA

Tables

Table 2.1. Selected Nucleic Acid-Amplification Technologies, and Selected Companies Utilizing These Technologies

Table 2.2. Selected Companies Developing and/or Marketing Clinical Molecular Diagnostic Products Based on Microarray Technology

Table 3.1. Selected Companies Developing and/or Marketing Molecular Diagnostics Tests for Infectious Disease

Table 3.2. Selected Companies Developing and/or Marketing Molecular Diagnostics Tests for Oncology Including Solid Tumors and Hematological Cancers

Table 3.3. Selected Companies Developing and/or Marketing Molecular Diagnostics Tests for Inherited Disease or Prenatal Diagnostics

Table 3.4. Selected Companies Developing and/or Marketing Molecular Diagnostics Tests for Prediction of Disease Risk

Table 3.5. Selected Companies Developing and/or Marketing Molecular Diagnostic Tests for Pharmacogenomics

Table 4.1. Selected Recent Acquisitions in Molecular Diagnostics

Figures

Figure 4.1. U.S. Clinical Laboratory Molecular Diagnostics Services Market

Figure 1A. Organizations Represented by Respondents

Figure 2A. Areas of Expertise

Figure 3A. Positions Within Organizations

Figure 4A. Use of Technologies

Figure 5A. Current Major Application Areas

Figure 6A. Growth Areas Next 2 Years

Figure 7A. Growth Areas Next 5 Years

Figure 8A. In-House vs. Outsourced Research

Figure 9A. Launching of Molecular Tests

Figure 10A. Launching of Molecular Tests as Reagents

Figure 11A. New Products with FDA Clearance or Approval

Figure 12A. Plans to Seek FDA Clearance or Approval

Figure 13A. Competitive Trends and Biomarkers

Figure 14A. Collaboration Trends